ClinicaliQ Trial Snapshot
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Recruiting • Infectious Disease • NCT05234723.
- What is being tested: Risk factors and clinical characteristics associated with ganciclovir-resistant or refractory cytomegalovirus (CMV) infection in immunocompromised patients following solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).
- Patient eligibility overview: The study includes transplant recipients (SOT or HSCT patients) who have developed documented CMV infection, with cases identified as ganciclovir-resistant/refractory compared against control cases of standard CMV infection.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
Eligibility Snapshot
- : * All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC * Ability to understand the purpose of the study and provide signed and dated informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.